Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIT II study in high-risk pMMR/MSS locally advanced rectal adenocarcinoma
ChiCTR2600132933Phase 3Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mFOLFOX6, cetuximab, bevacizumab and PD-1 Monoclonal Antibody in rectal adenocarcinoma (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: 3-year disease-free survival. Started Apr 2026; status: recruiting.
02
Drugs
mFOLFOX6cetuximabbevacizumabPD-1 Monoclonal Antibody
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600132933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132933.